ADCYAP1 and diabetic neuropathy: These data suggest that PACAP, in spite of its effects on glucose homeostasis and insulin secretion [53,54], is protective in our diabetic neuropathy model, not by acting directly on glucose levels, but most probably due to its neuro- and general cytoprotective effects [20,79].